Cargando…

Stem cell-based therapy for human diseases

Recent advancements in stem cell technology open a new door for patients suffering from diseases and disorders that have yet to be treated. Stem cell-based therapy, including human pluripotent stem cells (hPSCs) and multipotent mesenchymal stem cells (MSCs), has recently emerged as a key player in r...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoang, Duc M., Pham, Phuong T., Bach, Trung Q., Ngo, Anh T. L., Nguyen, Quyen T., Phan, Trang T. K., Nguyen, Giang H., Le, Phuong T. T., Hoang, Van T., Forsyth, Nicholas R., Heke, Michael, Nguyen, Liem Thanh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357075/
https://www.ncbi.nlm.nih.gov/pubmed/35933430
http://dx.doi.org/10.1038/s41392-022-01134-4
_version_ 1784763660516720640
author Hoang, Duc M.
Pham, Phuong T.
Bach, Trung Q.
Ngo, Anh T. L.
Nguyen, Quyen T.
Phan, Trang T. K.
Nguyen, Giang H.
Le, Phuong T. T.
Hoang, Van T.
Forsyth, Nicholas R.
Heke, Michael
Nguyen, Liem Thanh
author_facet Hoang, Duc M.
Pham, Phuong T.
Bach, Trung Q.
Ngo, Anh T. L.
Nguyen, Quyen T.
Phan, Trang T. K.
Nguyen, Giang H.
Le, Phuong T. T.
Hoang, Van T.
Forsyth, Nicholas R.
Heke, Michael
Nguyen, Liem Thanh
author_sort Hoang, Duc M.
collection PubMed
description Recent advancements in stem cell technology open a new door for patients suffering from diseases and disorders that have yet to be treated. Stem cell-based therapy, including human pluripotent stem cells (hPSCs) and multipotent mesenchymal stem cells (MSCs), has recently emerged as a key player in regenerative medicine. hPSCs are defined as self-renewable cell types conferring the ability to differentiate into various cellular phenotypes of the human body, including three germ layers. MSCs are multipotent progenitor cells possessing self-renewal ability (limited in vitro) and differentiation potential into mesenchymal lineages, according to the International Society for Cell and Gene Therapy (ISCT). This review provides an update on recent clinical applications using either hPSCs or MSCs derived from bone marrow (BM), adipose tissue (AT), or the umbilical cord (UC) for the treatment of human diseases, including neurological disorders, pulmonary dysfunctions, metabolic/endocrine-related diseases, reproductive disorders, skin burns, and cardiovascular conditions. Moreover, we discuss our own clinical trial experiences on targeted therapies using MSCs in a clinical setting, and we propose and discuss the MSC tissue origin concept and how MSC origin may contribute to the role of MSCs in downstream applications, with the ultimate objective of facilitating translational research in regenerative medicine into clinical applications. The mechanisms discussed here support the proposed hypothesis that BM-MSCs are potentially good candidates for brain and spinal cord injury treatment, AT-MSCs are potentially good candidates for reproductive disorder treatment and skin regeneration, and UC-MSCs are potentially good candidates for pulmonary disease and acute respiratory distress syndrome treatment.
format Online
Article
Text
id pubmed-9357075
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-93570752022-08-08 Stem cell-based therapy for human diseases Hoang, Duc M. Pham, Phuong T. Bach, Trung Q. Ngo, Anh T. L. Nguyen, Quyen T. Phan, Trang T. K. Nguyen, Giang H. Le, Phuong T. T. Hoang, Van T. Forsyth, Nicholas R. Heke, Michael Nguyen, Liem Thanh Signal Transduct Target Ther Review Article Recent advancements in stem cell technology open a new door for patients suffering from diseases and disorders that have yet to be treated. Stem cell-based therapy, including human pluripotent stem cells (hPSCs) and multipotent mesenchymal stem cells (MSCs), has recently emerged as a key player in regenerative medicine. hPSCs are defined as self-renewable cell types conferring the ability to differentiate into various cellular phenotypes of the human body, including three germ layers. MSCs are multipotent progenitor cells possessing self-renewal ability (limited in vitro) and differentiation potential into mesenchymal lineages, according to the International Society for Cell and Gene Therapy (ISCT). This review provides an update on recent clinical applications using either hPSCs or MSCs derived from bone marrow (BM), adipose tissue (AT), or the umbilical cord (UC) for the treatment of human diseases, including neurological disorders, pulmonary dysfunctions, metabolic/endocrine-related diseases, reproductive disorders, skin burns, and cardiovascular conditions. Moreover, we discuss our own clinical trial experiences on targeted therapies using MSCs in a clinical setting, and we propose and discuss the MSC tissue origin concept and how MSC origin may contribute to the role of MSCs in downstream applications, with the ultimate objective of facilitating translational research in regenerative medicine into clinical applications. The mechanisms discussed here support the proposed hypothesis that BM-MSCs are potentially good candidates for brain and spinal cord injury treatment, AT-MSCs are potentially good candidates for reproductive disorder treatment and skin regeneration, and UC-MSCs are potentially good candidates for pulmonary disease and acute respiratory distress syndrome treatment. Nature Publishing Group UK 2022-08-06 /pmc/articles/PMC9357075/ /pubmed/35933430 http://dx.doi.org/10.1038/s41392-022-01134-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Hoang, Duc M.
Pham, Phuong T.
Bach, Trung Q.
Ngo, Anh T. L.
Nguyen, Quyen T.
Phan, Trang T. K.
Nguyen, Giang H.
Le, Phuong T. T.
Hoang, Van T.
Forsyth, Nicholas R.
Heke, Michael
Nguyen, Liem Thanh
Stem cell-based therapy for human diseases
title Stem cell-based therapy for human diseases
title_full Stem cell-based therapy for human diseases
title_fullStr Stem cell-based therapy for human diseases
title_full_unstemmed Stem cell-based therapy for human diseases
title_short Stem cell-based therapy for human diseases
title_sort stem cell-based therapy for human diseases
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357075/
https://www.ncbi.nlm.nih.gov/pubmed/35933430
http://dx.doi.org/10.1038/s41392-022-01134-4
work_keys_str_mv AT hoangducm stemcellbasedtherapyforhumandiseases
AT phamphuongt stemcellbasedtherapyforhumandiseases
AT bachtrungq stemcellbasedtherapyforhumandiseases
AT ngoanhtl stemcellbasedtherapyforhumandiseases
AT nguyenquyent stemcellbasedtherapyforhumandiseases
AT phantrangtk stemcellbasedtherapyforhumandiseases
AT nguyengiangh stemcellbasedtherapyforhumandiseases
AT lephuongtt stemcellbasedtherapyforhumandiseases
AT hoangvant stemcellbasedtherapyforhumandiseases
AT forsythnicholasr stemcellbasedtherapyforhumandiseases
AT hekemichael stemcellbasedtherapyforhumandiseases
AT nguyenliemthanh stemcellbasedtherapyforhumandiseases